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ABSTRACT
Background and Aims Due to concerns about increased exposure to nicotine, pregnant women using nicotine
replacement therapy (NRT) to stop smoking are usually advised to stop using NRT if they relapse to smoking. This study
investigatedwhether this is justiﬁed.We compared changes in saliva cotinine from baseline to 2weeks post-target quit date
pregnant smokers who relapsed to smoking and continued to use their patches having been assigned to use nicotine
patches or placebo. Design and Setting Controlled pre–post design stratiﬁed by intervention condition from the ‘Study
of Nicotine Patch in Pregnancy’, a randomized, placebo-controlled trial.Participants A sample of 268 pregnantwomen,
assigned placebo (n = 122) or nicotine (n = 146) patches, who returned for further supplies of patches and who reported
any smoking in the week prior to a visit at 2 weeks after their target quit date. Measurements Saliva cotinine
concentrations were measured at baseline and 2 weeks after participants’ target quit dates. Any smoking in the previous
weekwas assessed by self-report, validated by expired air carbonmonoxide (CO). Findings Therewas no change in saliva
cotinine concentrations between baseline and 2 weeks post-target quit date in saliva cotinine concentration in the
nicotine patch group [ratio of geometric means = 0.94, 95% conﬁdence interval (CI) = 0.83 to 1.07; P = 0.37, Bayes
factor = 0.15]. However, there was a reduction in reported number of cigarettes smoked/day (mean difference 6, 95%
CIs 7 to 5, P < 0.001) and in CO concentrations (mean difference 3.0 parts per million, 95% CIs 4.2 to 1.9,
P < 0.001). These changes were not signiﬁcantly different from changes in the placebo group except for cigarette
consumption, which reduced more in the nicotine group (P = 0.046). Conclusions In women trying to stop
smoking with the aid of a nicotine patch but having smoked at 2 weeks post-target quit, their nicotine concentration
did not change from baseline, but they reported smoking fewer cigarettes and had lower carbon monoxide concentrations.
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INTRODUCTION
Smoking during pregnancy is the leading modiﬁable risk
factor for poor maternal and infant health outcomes.
Pregnancy-related health problems associated with
smoking during pregnancy include complications during
labour, increased risk of miscarriage, premature birth,
stillbirth and low birth weight [1–3]. Despite this, ap-
proximately 12% of pregnant women in the United
Kingdom, 13% in the United States and 20% in
France continue to smoke during pregnancy [4–6]. Sev-
eral national guidelines have adopted using nicotine re-
placement therapy (NRT) for supporting pregnant
smokers to quit, based on the idea that NRT is probably
safer than smoking as it does not contain the toxins
present in tobacco smoke [7,8].
While NRT has been proven to be effective in non-
pregnant smokers [9], its efﬁcacy in pregnancy is uncer-
tain [10]. The reason for this uncertainty is unclear;
however, it is hypothesized that physiological changes in
pregnancy could affect nicotine’s metabolism [11]. Poten-
tial factors for the increased metabolism rate include a
higher concentration or activity of metabolic enzymes in-
volved and increased blood ﬂow through the liver during
pregnancy [12]. Cotinine is the principal metabolite of nic-
otine, and the clearance of nicotine and cotinine is 60 and
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140% higher, respectively, during pregnancy [13]. An in-
crease inmetabolic rate could signify that nicotine supplied
through standard dose NRTmay be insufﬁcient to alleviate
smoking withdrawal symptoms in pregnancy and to pro-
vide therapeutic effects.
A systematic review and meta-analysis comparing nic-
otine exposure in pregnant women when smoking, and
their nicotine exposure when abstinent and using NRT,
found that NRT exposes women to lower doses of nicotine
than does smoking [14]. Generally, in studies included in
this review, such as the Smoking, Nicotine and Pregnancy
(SNAP) trial, women were instructed to discontinue use of
nicotine patches if they had even brief smoking lapses [15].
This mimics routine health care, where pregnant women
are usually advised to stop using NRT if they lapse to
smoking, even for short periods. There is concern that con-
comitant smoking and NRT use could increase exposure to
nicotine and potentially more tobacco smoke toxins if they
smoked heavily when using NRT. However, in pregnancy
this assumption is untested, and we know little about
women’s smoking behaviour when they use NRT concur-
rently. This is important, as women who lapse to smoking
may still want to quit. In a non-pregnant population, con-
tinued use of nicotine patches has been found to promote
recovery from lapses [16]; if this is the case during
pregnancy, women may have better chances of cessation
if NRT is continued.
This study aims to investigate and compare: (1)
changes in saliva cotinine and other indicators of smoking
intensity in women using nicotine or placebo patches and
smoking concurrently with those when they only smoked;
and (2) whether these changes differed between nicotine
and placebo patch use.
METHODS
Design
This is a secondary analysis of data from the Study of Nic-
otine Patch in Pregnancy (SNIPP) [17]. SNIPP was a
multi-centre, double-blind, randomized, placebo-controlled
study conducted in France using 16-hour nicotine patches.
The trial randomized 402 women to either nicotine
(n = 203) or placebo patches (n = 199). The study was ap-
proved by the Ethics Committee of the Pitié-Salpêtrière
Hospital, Paris, France.
Participants
Participants were eligible for inclusion in the SNIPP trial if
they smoked at least ﬁve cigarettes per day, were agedmore
than 18 years, of 12–20 weeks’ gestation and scored at
least 5 on a scale measuring motivation to stop smoking
(range 0–10) [17]. Prior to enrolment, participants
attended a baseline visit where demographic, obstetric,
physiological characteristics and smoking behaviour data
were collected, and saliva cotinine concentrations were de-
termined. At this stage, participants were given 2 weeks to
quit smoking or reduce the number of cigarettes to fewer
than ﬁve a day. If after this 2-week period they were unable
to do either of these they could be randomized, receive the
study drug and set a quit date when treatment began. Par-
ticipants were asked to stop smoking on a pre-deﬁned quit
date and were randomized to either placebo or nicotine
patches. Participants were told that they could continue
using nicotine patches during smoking lapses. Moreover,
patch doses were adjusted according to the previous saliva
cotinine determination to optimize the nicotine substitu-
tion; this resulted in participants receiving a mean nicotine
dose of 18 mg/day [standard deviation (SD) = 6.8] in the
nicotine patch arm.
Measures
In the SNIPP trial, abstinence was deﬁned as self-reported
abstinence, conﬁrmed by expired air carbon monoxide
(CO) concentration ≤ 8 parts per million (p.p.m.)
(Smokeanalyzer®; Bedfont Scientiﬁc Ltd, Rochester, Kent,
UK) [18]. Saliva cotinine samples were collected by placing
a cotton roll in the gingival cleft for 1 minute, which was
then placed immediately into a Salivette tube (Sarstedt,
Nümbrecht, Germany) [18]. Samples were kept at 4°C
and were sent to the central biochemistry laboratory
(Hôpital Pitié-Salpêtrière, Laboratoire de Biochimie, Dr N.
Jacob) within 24 hours for determination [18]. The quan-
tiﬁcation limit for cotinine was 7.5 mg/l and the between-
run coefﬁcient of variation 5–8% [18].
Figure 1 showswhen trial visits occurred andmeasure-
ments were made. Saliva cotinine concentrations were de-
termined at baseline, 2 weeks after quit date and 8 weeks
after quit date, with nicotine doses adjusted after each of
these visits at 4 and 12 weeks after quit date, respectively.
Nicotine doses were adjusted using a conversion factor of
0.1. For example, a saliva cotinine concentration of
100 ng/l equated to a prescription of one 10-mg patch
[17]. At baseline, body mass index (BMI), gestational age,
ethnicity and Fagerström Test for Cigarette Dependence
(FTCD) scores were recorded. Aswell as at baseline, at each
visit women reported any smoking in the previous week,
validated by expired air CO. Additionally, intensity of crav-
ing for tobacco via the French Tobacco Craving Question-
naire, 12 items (FTCQ-12) and the number of cigarettes
smoked by the participant in the last week were assessed.
The SNIPP trial recorded cigarette consumption in the past
week, rather than cigarettes per day, due to large day-to-
day ﬂuctuations in cigarette consumption [19,20]. Partner
smoking in the previous week was also assessed, as the
second-hand smoke exposure is likely to increase cotinine
measures. Women were permitted to use nicotine patches
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from quit date until delivery. A more extensive description
is available elsewhere [17].
In this study we used data from women collected at
2weeks after the quit date who had been allocated nicotine
or placebo patches but who reported any smoking in the
previous week. A second sample of data collected at
8 weeks after the quit date from women who had smoked
in the previous week were used as a sensitivity analysis.
Not all women who had cotinine measured at 2 weeks
returned for the 8-week visit, and 8-week data also in-
cluded women who did not return at 2 weeks. We selected
women from 2 weeks rather than 8 weeks after the quit
date for the main analysis, as this time-point was earlier
in gestation, so nicotine metabolism changes since the
baseline visit would probably be small and have less impact
on ﬁndings [21].
Analyses
For baseline data, continuous measures were reported as
means with SDs, and categorical measures were reported
using frequencies and percentages. Participant and part-
ner’s smoking in the previous week were divided by 7 to
achieve cigarettes smoked per day. T-tests were used to as-
sess whether there were any systematic differences in base-
line characteristics between women who were included
and those excluded from this study. We used a natural
log-transformation of salivary cotinine concentrations to
achieve a normal distribution.
For both nicotine and placebo patch groups we used
paired t-tests to assess ‘within-participant’ differences be-
tween cotinine, CO, cravings, number of cigarettes smoked
by the participant and number of cigarettes smoked by
their partner, measured at baseline and at 2 weeks. The
same analyses were conducted using data from 8 weeks.
For saliva cotinine, we present the back-transformed esti-
mates of treatment differences, which is the ratio of the
geometric means. Next, we used linear regression analysis
to test for an interaction between the measures mentioned
above and nicotine patch assignment. We then aimed to
identify whether the interactions were signiﬁcant at in-
creasing increments of baseline values in cotinine, CO,
cravings, number of cigarettes smoked by the participant
and number of cigarettes smoked by their partner. Findings
are presented graphically. P-values less than 0.05 were
deemed statistically signiﬁcant. All analyses were con-
ducted using Stata version 15.
After undertaking the planned analyses we generated a
Bayes factor from the difference in saliva cotinine, using an
online calculator [22]. We were unable to identify any
studies that investigated nicotine intake of concurrent
smokers and NRT users in pregnancy, so an expected
difference of 139.3 ng/ml was taken from a study of nico-
tine intake outside pregnancy [23].We used a conservative
approach for estimation using a half-normal distribution,
where the standard deviation is equal to the expected
effect size.
RESULTS
In the SNIPP trial, 203 women were assigned to the nico-
tine patch arm and 199 women were assigned to the pla-
cebo patch arm. At 2 weeks after the quit date, 167
(82.3%) and 148 (74.4%) women returned for the visit
in the nicotine patch and placebo patch arms, respectively.
In the nicotine patch arm, 149 (73.4%) had smoked in the
week prior to the visit and 18 (8.9%) were abstinent
whereas, in the placebo group, 131 (65.8%) had smoked
during the week prior to the visit and 17 (8.5%) were absti-
nent. Overall, 12 women had missing cotinine data at this
point andwere excluded from the study, leaving a sample of
Figure 1 Flow-chart to show each planned visit in the ‘Study of
Nicotine Patch in Pregnancy’ relevant to the current study
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268 for analysis (146 in the nicotine group and 122 in the
placebo group).
When comparing SNIPP trial participants excluded
from this studywith those included, it was found that more
women in this study had a partner who smoked. Table 1
gives baseline characteristics of women in both study
groups and, using these descriptors, both groups were
broadly similar. From the participants who provided 2-
week data, those assigned nicotine patch had a mean age
of 30 years and gestational age at baseline of 12.8 weeks;
therefore, their mean gestational age at 2 weeks post-quit
date would be between 16 and 17 weeks.
Table 2 compares indicators of smoking intensity
between baseline and 2 weeks after the quit date for
pregnant smokers in both the placebo and nicotine patch
groups. In the nicotine group there was no signiﬁcant dif-
ference between cotinine concentrations [ratio of
geometric means = 0.94 ng/ml, 95% conﬁdence interval
(CI) = 0.83–1.07 ng/ml; P = 0.37, Bayes factor = 0.15],
Table 1 Participant baseline characteristics; n (%) or mean
(standard deviation).
Characteristic
Women on nicotine
patch (n = 146)
Women on placebo
patch (n = 122)
Age (years) 29.70 (6.00) 28.88 (5.03)
BMI (kg/m2) 25.52 (5.40) 25.21 (5.33)
Gestational age at
baseline (weeks)
12.8 (3.2) 12.6 (5.4)
Ethnicity
European 139 (95) 115 (94)
African 4 (3) 4 (3)
Asian 1 (1) 1 (1)
Other 2 (1) 2 (2)
Current cigarettes smoking per day
5–10 66 (45) 55 (45)
11–20 69 (47) 50 (41)
21–30 7 (5) 16 (13)
>30 4 (3) 1 (1)
Fagerström Test for Cigarette Dependencea
Very low 32 (22) 20 (16)
Low 34 (23) 42 (34)
Medium 29 (20) 18 (15)
High 43 (29) 33 (27)
Very high 8 (6) 9 (7)
Partner smoking
Yes 99 (69) 90 (75)
Saliva cotinine (ng/ml) 143.86 (82.81) 144.36 (74.33)
Expired air carbon
monoxide (p.p.m.)
11.8 (6.7) 12.2 (7.3)
French Tobacco Craving
Questionnaire score
33.64 (8.60) 35.55 (9.53)
aFagerström Test for Cigarette Dependence is a six-item test where answers
are summed to yield a total score of 0–10. The higher the total score, the
more intense is the patient’s physical dependence on cigarettes; i.e. a score
between 0–2 indicates a very low level of dependence on cigarettes, and
8–10 indicates a very high-level dependence on cigarettes [24]. BMI = body
mass index; p.p.m. = parts per million. Ta
bl
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but CO concentrations signiﬁcantly decreased from
baseline to 2 weeks after the quit date (mean
difference  3.0 p.p.m., 95% CI = 4.2 to 1.9 p.p.m.;
P < 0.001), whereas the placebo group exhibited a
signiﬁcant reduction in cotinine (ratio of geometric
means = 0.68 ng/ml, 95% CI = 0.59–0.78 ng/ml;
P < 0.001) as well as a reduction in CO concentration
(mean difference = 2.0 p.p.m., 95% CI = 3.8 to
0.2 p.p.m., P < 0.028). There were also signiﬁcantly
lower levels of craving, lower numbers of cigarettes smoked
in the previous week and women’s partners were reported
to have smoked fewer cigarettes in both nicotine and
placebo patch groups.
Table 2 also reports results for interaction tests between
the indicators of smoking intensity and nicotine patch as-
signment. There was a signiﬁcant interaction between nic-
otine patch assignment and a reduction in number of
cigarettes smoked (P = 0.046). This means that women
assigned nicotine patches smoked less at week 2 compared
to women assigned placebo patches. Interactions between
the remaining indicators of smoking intensity and nicotine
patch assignment were not signiﬁcant. Upon further
exploration it was discovered that there was an interaction
between nicotine patch assignment and women with
higher baseline cotinine concentrations (Fig. 2). Women
assigned nicotine patches with baseline saliva cotinine
concentrations of approximately 90 ng/ml and above had
higher cotinine concentrations at week 2 compared to
women assigned placebo patches.
In the sensitivity analysis, the 8-week data showed a
similar pattern to the 2-week data (Supporting informa-
tion, Table S1). Therewas no signiﬁcant difference between
cotinine concentrations at baseline and 8 weeks in the
nicotine patch group (ratio of geometric
means = 0.85 ng/ml, 95% CI = 0.71–1.00 ng/ml;
P=0.055, Bayes factor =0.12); however, therewere signif-
icant reductions for all other indicators of smoking intensity
aside from craving score (mean difference = 1.69, 95%
CI=3.58 to 0.20P=0.079). Inwomen assigned placebo
patches, there were signiﬁcant reductions for all indicators
of smoking cessation aside from expired CO concentration
(mean difference  2.4 p.p.m., 95% CI =  5.0 to 0.3 p.p.
m., P < 0.077). The interaction tests found no signiﬁcant
interaction for nicotine patch assignment; however, graph-
ical exploration found that there was a signiﬁcant interac-
tion for nicotine patch assignment and participants who
reported smoking between 100 and 250 cigarettes a week
at baseline (Supporting information, Fig. S1); in these
women, assignment to nicotine patch was associated with
having smoked fewer cigarettes in the previous 7 days.
DISCUSSION
Our ﬁndings show that women prescribed nicotine patches
but who also admitted smoking had similar cotinine con-
centrations to those generated when they only smoked.
Thesewomen also reported smoking less and had lower ex-
pired air CO readings thanwhen they smoked prior to their
quit attempt. In comparison, smokers issued with placebo
patches had lower cotinine concentrations than when
smoking; they also showed reductions in numbers of ciga-
rettes smoked and expired CO concentrations. Our results
also indicate that women who smoke and use nicotine
patches smoke less later in pregnancy.
A limitation to our study is that, while we know that
women included in this study were prescribed nicotine
patches, we have very limited information about howmuch
these were used. However, as study measurements at 2-
and 8-week follow up were taken with the intention of
personalizing the nicotine doses which women received
from patches, it seems very likely that women who attended
these appointments were still using these. Furthermore,
the SNIPP trial also reports (where adherence data exists)
that the median self-reported adherence rate was 85% [17].
Another possible limitation concerns the validity of
women’s reports of smoking or not smoking during the
week prior to having 2- and 8-week measurements taken.
In SNIPP, women were deﬁned as smokers if they had re-
ported any smoking in the week prior to a study visit,
and this was validated by an expired CO reading. However,
expired air CO can only reliably validate smoking status
during the previous 6 hours [25] and, although some
women may have over- or underestimated the number of
cigarettes smoked in the previous week, we could only ac-
curately quantify tobacco smoke exposure in the 6 hours
prior to CO measurement. Nevertheless, this could only
have had a major impact on ﬁndings if women generally
Figure 2 Graph to show interaction of nicotine patches on cotinine
concentrations at 2 weeks with increasing baseline cotinine concentra-
tions. The shaded area represents the 95% conﬁdence intervals. As
the shaded area for log cotinine > 4.5 is above 0, there is a signiﬁcant
interaction of nicotine patches for an increase in cotinine at 2 weeks in
women with log cotinine concentrations of greater than 4.5 (back-trans-
formed to 90 ng/ml), compared with placebo [Colour ﬁgure can be
viewed at wileyonlinelibrary.com]
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under-reported their smoking during the week prior to
follow-up appointments and, in the 6 hours before follow-
up appointments, tried to smoke less than they had re-
ported. It seems unlikely that trial participants would do
this before attending a nicotine patch dose-titration
appointment.
A strength of this study is that the data were obtained
as part of a well-conducted randomized controlled trial
and included reported smoking behaviour with concurrent
CO and cotinine estimation at several time-points. To our
knowledge, there has been no previous study that has
investigated smoking behaviour and CO exposure from
concurrent use of nicotine patches and smoking in
pregnancy. Hence, we believe this makes an original contri-
bution to the ﬁeld. Another strength is that comparisons
are based on ‘within-participant’ measurements; this
means that inter-participant variations are very unlikely
to explain study ﬁndings. Indeed, with this study design
one would only expect ﬁndings to be affected by character-
istics of womenwhich were prone to change between base-
line and follow-up. Women’s nicotine metabolic rates
(NMR) increase as pregnancy progresses, and these would
be expected to affect their plasma nicotine concentrations
and so, potentially, also their cravings and intensity of
smoking [13,21]. However, any effect would seem to be
marginal as, even in the placebo group, women reported
smoking fewer cigarettes. Also, as pregnancy-related
NMR acceleration is generally complete by the end of the
ﬁrst trimester and women’s mean gestation at baseline
was ~13 weeks, there may have been little scope for this
factor to have any inﬂuence. It seems likely, therefore, that
the differences reported reﬂect differences in smoking be-
haviour and not changes in women’s physiology during
pregnancy.
Our study informs about cotinine concentrations in
pregnant women who use nicotine patches but are not ab-
stinent from smoking, and show that cotinine concentra-
tions in such women were no higher than when they
were smoking. Additionally, women included in this study
had simultaneous and statistically signiﬁcant reductions
in their cigarette use, validated by a reduction in expired
CO. This suggests that when pregnant women use nicotine
patches and smoke, they smoke less than theywould if they
were not using nicotine patches. This is important, as it
could inﬂuence how women are advised to use NRT in
pregnancy, i.e. encouraged to continue using NRT despite
a relapse.
We are unaware of any previous studies measuring
cotinine or CO in smokers who concurrently use NRT
during pregnancy. A systematic review and meta-analysis
that aimed to identify and describe studies which report
nicotine or cotinine concentrations in pregnant women
when smoking, and subsequently when abstinent from
smoking and using NRT, concluded that among pregnant
women who quit smoking, standard-dose NRT generates
lower nicotine exposure than smoking [14]. The meta-
analysis compared cotinine exposures when pregnant
women smoke with those when they use NRT and found
that concentrations were, on average, 75.3 ng/ml lower
when abstinent and using NRT than when the same
women smoked [14]. In SNIPP, salivary cotinine concen-
trations at baseline (when smoking) were compared to
cotinine concentrations at 1 month in women who had
stopped smoking but were using nicotine patches. Cotin-
ine concentrations were 98.5 ng/ml while smoking, but
only 62.8 ng/ml while using nicotine patches [17]. In
our study we found that women who were assigned the
placebo patch but admitted to smoking also exhibited re-
duced cotinine concentrations compared to those when
smoking alone.
Most studies in the above review used lower nicotine
doses than were used by participants in this paper’s analy-
ses; other than SNIPP, studies used standard rather than
higher doses of nicotine, and these delivered no more than
15 mg cotinine in 16 hours or the 24-hour equivalent
[14]. Thus, when pregnant smokers become abstinent
and adhere with such ‘standard’ doses of NRT they are,
on average, exposed to less nicotine than from smoking
[14]. In SNIPP, patch doses were adjusted according to
the previous saliva cotinine determination to optimize the
nicotine substitution leading to somewhat higher mean
nicotine doses than usual (18 mg/day, SD = 6.8). It is
expected that the dose adjustment would improve nicotine
substitution, thus it is possible that women assigned
nicotine patches in the 8-week sample would have higher
cotinine concentrations than they had at baseline. Despite
this adjustment, there was no signiﬁcant difference in
cotinine concentrations in women who were assigned
nicotine patches and admitted to smoking compared to
those when smoking alone. This also suggests that
smoking and using nicotine patches of ‘standard’ doses
may lead to lower cotinine concentrations during preg-
nancy than smoking alone, prior to pregnancy.
Our ﬁndings provide the ﬁrst data we are aware of
which quantiﬁes pregnant women’s smoking behaviour
when using nicotine patches, and this suggests that when
pregnant women use nicotine patches as part of a quit at-
tempt, but also smoke, they smoke less than they did before
the quit attempt started. This means that their exposure to
the toxic products of burnt tobacco is reduced. A possible
reason for this is that womenwho continue to smokewhen
using nicotine patches obtain nicotine from both patches
and tobacco, and nicotine delivered from patches reduces
women’s cravings such that they feel less need to ‘top up’
concentrations of nicotine in their body ﬂuids through
smoking. This suggests that clinicians can reassure women
that it is alright to smoke and use nicotine patches if, ulti-
mately, they are trying for abstinence.
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CONCLUSIONS
In conclusion, despite having similar cotinine exposure to
that from cigarette smoking, pregnant women who use
nicotine patches and smoke, smoke less and exhale less
CO, so their exposure to other tobacco smoke toxins is also
likely to be lower.
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Supporting Information
Additional supporting information may be found online in
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Table S1 Baseline to 8-weeks after the quit date ‘within-
participant’ differences in indicators of smoking intensity
in pregnant smokers by treatment group, with a signiﬁ-
cance test for interaction with nicotine patch
Figure S1Graph to show interaction of nicotine patches on
cigarettes smoked at 2-weeks with increasing number of
cigarettes smoked at baseline. The shaded area represents
the 95% conﬁdence intervals. As the shaded area for num-
ber of cigarettes smoked between 100–250, is below 0,
there is a signiﬁcant interaction of nicotine patches for a re-
duction of cigarettes smoked at 8-weeks in women that
smoked between 100–250 cigarettes in the week prior to
baseline compared with placebo.
8 Ravinder Claire et al.
© 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction Addiction
